Table 6. Outcomes in New World leishmaniasis studies.
| Year, Author | Study arms (number of patients) | Epithelialization rate between 30–73 days, number of patients (%) | Epithelialization rate between 74–100 days, number of patients (%) | Epithelialization rate between 101–194 days, number of patients (%) | Follow-up lost | Relapse after cure |
|---|---|---|---|---|---|---|
| 2016, da Silva | MA-IL (31) | - | 21/31 | 22/31 | - | - |
| 2016, Soto A | SSG 3-IL (30) | 4/30 (13.3) | 17/30 (56.6) | - | 1/30 | 2/30 |
| SSG 5-IL (30) | 11/30 (36.6) | 20/30 (66.6) | - | - | 2/30 | |
| Penta-120-IL (30) | 12/30 (40) | 20/30 (66.6) | 21/30 (70) | 1/30 | 0/30 | |
| 2016, Soto B | SSG 5-IL (30) | 3/30 (10) | 16/30 (53.3) | 20/30 (66.6) | - | NR |
| Penta-240-3-IL (30) | 11/30 (36.6) | 22/30 (73.3) | - | 1/30 | - | |
| 2013, Soto | MA-IL (30) | 9/30 (30) | 21/30 (70) | - | 1/30 | - |
| Cryo (20) | 1/20 (5) | 4/20 (20) | 1/30 | - | ||
| Placebo cream (30) | 2/30 (6.6) | 5/30 (16.6) | 1/30 | 2/30 | ||
| 2012, Vasconcellos | MA-IL (24) | - | 20/24 (83.3) | - | 0/24 | NR |
| 1997, Oliveira-Neto | MA-IL (74) | - | 59/74 (79.7) | - | 3/74 | 0/56 |
| 1995, Yepéz | MA-IL (30) | 25/30 (83.3) | - | - | 1/30 | NR |
| MA-IL+ Lidocaine (29) | 29/29 (100) | 0/29 | ||||
| Lidocaine (30) | 28/30 (93.3) | 1/30 | ||||
| 1995, Gadelha | MA-IL (64) | 60/64 (93.7) | - | - | 3/64 | NR |
NR: no reported Cryo: Cryotherapy MA-IL: intralesional meglumine antimoniate Penta120-IL: intralesional pentamidine (120 mg/mm2 of lesion area) for 3 injections Penta 240-3-IL: intralesional pentamidine (240 mg/mm2 of lesion area) in 3 injections SSG-IL: intralesional sodium stibogluconate SSG 3-IL: intralesional sodium stibogluconate for 3 injections SSG 5-IL: intralesional sodium stibogluconate in 5 injections